AtriCure (ATRC) Tops Q2 EPS by 37c

AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.20), $0.37 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $40.8 million versus the consensus estimate of $35.95 million.

2020 Financial Guidance

As previously reported, AtriCure is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue